Nanobiotix 2018 Annual Results - Seite 4
Collaboration in preclinical research
Collaboration with the Providence Cancer Institute
Nanobiotix partnered with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancer. This collaboration will provide essential preclinical data on the ability of NBTXR3 activated by radiotherapy to induce an antitumoral immune response.
_______________
2 The Company’s statutory auditors have completed their audit work on the 2018 financial statements and expect to issue their audit report on March 20th, 2019.
The University of Texas MD Anderson Cancer Center and Nanobiotix have an agreement in pre-clinical research
Nanobiotix and the University of Texas MD Anderson Cancer Center have an agreement to run immunotherapeutic pre-clinical research in lung cancer. The main objectives of this project, with one of the world’s leading oncology research centers, is to provide preclinical data using NBTXR3 activated by radiotherapy plus anti PD-1 Nivolumab (murine version of Opdivo).
Partnering with Weill Cornell Medicine on pre-clinical studies
Lesen Sie auch
Nanobiotix and Weill Cornell Medicine partnered to perform pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers. The main objective is to study the impact of NBTXR3 activated by radiotherapy on cGAS-STING, a key component of the anti-tumor immune response. Data generated from this collaboration could provide support for the assertion that NBTXR3 activated by radiotherapy can increase the anti-tumor immune response compared to radiotherapy alone.
Preclinical data showing NBTXR3 can activate cGAS-STING pathway
Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway at the American Association for Cancer Research (AACR). These observations support the rationale for using NBTXR3 with radiation therapy in combination with immunotherapeutic agents and/or STING agonist to transform tumors into an in-situ cancer vaccine.
Financial events
Launch of a €40M non-dilutive financing agreement with the European Investment Bank
Nanobiotix announced in July 2018, the launching of a non-dilutive financing agreement with the European Investment Bank to boost its research, development and innovation activities. This agreement will allow the Company to borrow up to €40M through loans before July 26, 2020 subject to achieving a set of agreed performance criteria.